Fiduciary Alliance LLC Has $7.99 Million Stock Position in Eli Lilly and Company $LLY

Key Points

• Fiduciary Alliance LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 40.5% in Q2, holding shares now valued at approximately $7.99 million.
• A variety of hedge funds have significantly adjusted their positions in Eli Lilly, showcasing strong institutional interest, with 82.53% of shares currently owned by institutional investors and hedge funds.
• Eli Lilly's recent earnings report revealed an earnings per share of $6.31, surpassing estimates, and the company has announced a quarterly dividend of $1.50 per share.

Fiduciary Alliance LLC boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 40.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 10,253 shares of the company's stock after purchasing an additional 2,954 shares during the period. Fiduciary Alliance LLC's holdings in Eli Lilly and Company were worth $7,993,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. WestEnd Advisors LLC lifted its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $27,000. Citizens National Bank Trust Department lifted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $43,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LLY has been the subject of several research reports. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 30th. Finally, Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $947.39.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $763.59 on Wednesday. The firm's fifty day moving average price is $740.25 and its two-hundred day moving average price is $774.23. The stock has a market cap of $722.71 billion, a PE ratio of 49.91, a PEG ratio of 1.04 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $939.86. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company's payout ratio is 39.22%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 in the last quarter. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.